Influence of intravitreal injections of HPMPC and related nucleoside analogues on intraocular pressure in guinea pig eyes

Investigative Ophthalmology and Visual Science

Volumn 39, Issue 7, 1998, Pages 1233-1242

  Banker, Alay S ^a   De Clercq, Erik ^b   Taskintuna, Ibrahim ^a   Keefe, Kelly S ^c   Bergeron Lynn, Germaine ^a   Freeman, William R ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^c NAVAL MEDICAL CENTER SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

9 (3 HYDROXY 2 PHOSPHONOMETHOXYPROPYL)ADENINE; CIDOFOVIR; NUCLEOSIDE ANALOG;

ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CILIARY BODY; CONTROLLED STUDY; DRUG POTENCY; EYE; GUINEA PIG; INTRAOCULAR PRESSURE; INTRAVITREAL DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; RETINA;

EID: 0031806391     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Jabs DA, Enger C, Bartlett JG. Cytomegalovirus retinitis and acquired immunodeficiency syndrome. Arch Ophthalmol. 1989;107: 75-80.
2. Holland GN, Buhles WC Jr, Mastre B, et al. A controlled prospective study of ganciclovir treatment for cytomegalovirus retinopathy: use of a standardized system for the assessment of disease outcome. Arch Ophthalmol. 1989;107:1759-1766.
3. Palestine AG, Polis MA, De Smet MD, et al. A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS. Ann Intern Med. 1991;115:665-673.
4. Drew WL, Ives D, Lalezari JP, et al. Syntex Cooperative Oral Ganciclovir Study Group. Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. N Engl J Med. 1995;333:615-620.
5. Spector SA, McKinley GF, Lalezari JP, et al. Roche Cooperative Oral Ganciclovir Study Group. Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. N Engl J Med. 1996;334:1491-1497.
6. Gross JG, Bozzette SA, Mathews WC, et al. Longitudinal study of cytomegalovirus retinitis in acquired immunodeficiency syndrome. Ophthalmology. 1990;97:681-686.
7. Studies of Ocular Complications of AIDS (SOCA) Research Group in collaboration with the AIDS Clinical Trials Group (ACTG). Studies of Ocular Complications of AIDS: mortality in patients with AIDS after treatment with either foscarnet or ganciclovir for cytomegalovirus retinitis. N Engl J Med. 1992;326:213-220.
8. Lalezari JP, Drew WL, Glutzer E, et al. (S)-1-[3-hydroxy-2-(phosphonylmethoxy) propy1] cytosine (cidofovir): results of a phase I/II study of a novel antiviral nucleotide analogue. J Infect Dis. 1995; 171:788-796.
9. Polis AM, Spooner KM, Baird BF, et al. Anticytomegaloviral activity and safety of cidofovir in patients with human immunodeficiency virus infection and cytomegalovirus viruria. Antimicrob Agents Chemother. 1995;39:882-886.
10. Arevalo JF, Gonzalez C, Caparelli EV, et al. Intravitreal and plasma concentrations after intravenous ganciclovir and foscarnet in patients with acquired immunodeficiency syndrome. J Infect Dis. 1995;172:451-456.
11. Rahhal FM, Arevalo JF, Chavez E, et al. Treatment of cytomegalovirus retinitis with intravitreous cidofovir in patients with AIDS. Ann Intern Med. 1996;125:98-103.
12. Besen G, Flores-Aguilar M, Kerry KA, et al. Long-term therapy of herpes retinitis in an animal model with high-concentrated liposome-encapsulated (HPMPC). Arch Ophthalmol. 1995;113:661-668.
13. Dolnak DR, Mungia D, Wiley CA, et al. Lack of retinal toxicity of the anti-cytomegalovirus drug (S)-1-(3-hydroxy-2-phosphonyl methoxypropyl) cytosine (HPMPC). Invest Ophthalmol Vis Sci. 1992;33:1557-1563.
14. Flores-Aguilar M, Huang JS, Wiley CA, et al. Long acting therapy of viral retinitis with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine (HPMPC). J Infect Dis. 1994;169:642-647.
15. Kuppermann BD, Assil KK, Vuong C, et al. Liposome-encapsulated (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine for long-acting therapy of viral retinitis. J Infect Dis. 1996;173:18-23.
16. Kirsch LS, Arevalo JF, Chavez E, et al. Intravitreal cidofovir (HPMPC) treatment of cytomegalovirus retinitis in patients with acquired immune deficiency syndrome. Ophthalmology. 1995; 102:533-543.
17. Kirsch LS, Arevalo JF, De Clercq E, et al. Phase I/II study of intravitreal cidofovir for the treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. Am J Ophthalmol. 1995;119:466-476.
18. Rahhal FM, Arevalo JF, Munguia D, et al. Intravitreal cidofovir (HPMPC) for the maintenance treatment of cytomegalovirus retinitis. Ophthalmology. 1996;103:1078-1083.
19. Taskintuna I, Banker AS, Rao NA, et al. An animal model for HPMPC (cidofovir) toxicity: intraocular pressure and histopathologic effects. Exp Eye Res. 1997;64:795-806.
20. Banker AS, Arevalo JF, Rahhal FM, et al. Intraocular pressure and aqueous humor dynamics in AIDS patients treated with intravitreal cidofovir (HPMPC) for cytomegalovirus retinitis. Am J Ophthalmol. 1997;124:168-180.
21. De Clercq E. Broad-spectrum anti-DNA and anti-retrovirus activity of phosphonylmethoxyalkylpurincs and pyrimidines. Biochem Pharmacol. 1991;42:963-972.
22. Shigeta S, Konno K, Baba M, Yokota T, De Clercq E. Comparative inhibitory effects of nucleoside analogs on different clinical isolates of human cytomegalovirus in vitro. J Infect Dis. 1991;163: 270-275.
23. Andrei G, Snoeck R, Reymen D, et al. Comparative activity of selected antiviral compounds against clinical isolates of human cytomegalovirus. Eur J Clin Microbiol Infect Dis. 1991;10: 1026-1033.
24. De Clercq E, Holy A, Rosenberg I, et al. A novel selective broad-spectrum anti-DNA virus agent. Nature. 1986;323:464-467.
25. Balzarini J, Holy A, Jindrich J, et al. Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine. Antimicrob Agents Chemother. 1993;37:332-338.
26. De Clercq E, Sakuma T, Baba M, et al. Antiviral activity of phosphonyl-methoxyalkyl derivatives of purine and pyrimidines. Antiviral Res. 1987;8:261-272.
27. Andrei G, Snoeck R, Goubau P, et al. Comparative activity of various compounds against clinical strains of herpes simplex virus. EurJ Clin Microbiol Infect Dis. 1992;11:143-151.
28. Andrei G, Snoeck R, Reymen D, et al. Comparative study of selected antiviral compounds against clinical isolates of varicella-zoster virus. EurJ Clin Microbiol Infect Dis. 1995;14: 318-328.
29. Bischofberger N, Hitchcock MJ, Chen MS, et al. 1-[(S)-2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-Y1) methyll cytosine, an intracellular prodrug for (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine with improved therapeutic index in vivo. Antimicrob Agents Chemotber. 1994;38:2387-2391.
30. Shakiba S, Freeman WR, Flores-Aguilar M, et al. Antiviral effect in human cytomegalovirus-infected cells, pharmacokinetics, and intravitreal toxicology in rabbits of acyclovir diphosphate dimyristoylglycerol. Antimicrob Agents Chemother. 1995;39: 1383-1385.